Exchange: OTC·Updated 05:28 PM EST

CURLF News

News
all
press releases
Should You Buy GTBIF Stock Following Q3 Earnings Results?
Green Thumb Industries' Q3 sales beat estimates despite an earnings miss, but pricing pressure and margin declines raise questions about its growth outlook.
Zacks
Should You Buy GTBIF Stock Following Q3 Earnings Results?
Green Thumb Industries' Q3 sales beat estimates despite an earnings miss, but pricing pressure and margin declines raise questions about its growth outlook.
Zacks
More News
Aurora Cannabis shares surged after Organigram agreed to a C$561 million buyout, but competing bids, deal conditions and shareholder uncertainty remain.
Zacks
Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of +12.50% and +1.79%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Organigram is set to acquire Aurora for C$7.80 per share, a 32.4% premium to the stock’s closing price on Monday.
Stocktwits
CURLF's hostile Aurora bid adds uncertainty as revenues recover, but margin pressure, rising costs and intense competition keep investors cautious.
Zacks
Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks and earnings pressures.
Zacks
TerrAscend's improving revenues, margins and cash flow support its recovery, while debt, competition and regulatory uncertainty remain key concerns.
Zacks
Tilray's revenues and EBITDA are growing, but weak margins, negative cash flow and competition raise questions about its next move.
Zacks
Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Zacks
Cresco's 10% monthly rally reflects stronger revenues, organic growth and margins, but competition and normalization risks cloud the outlook.
Zacks

Advertisement|Remove ads.